low-dose IL-2

4 · 20 / page

Ask MedXY AI

Latest news

Tag

Allergy & ImmunologyALSclinical trial

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

By MedXY|Dec 6, 2025

The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark

Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid

Dermatologylow-dose IL-2Regulatory T cells

low-dose IL-2

Latest news

Low-Dose Interleukin-2 as Adjunct to Riluzole in ALS: Insights from the Phase 2b MIROCALS Trial

Low-Dose Interleukin-2 Accelerates Disease Control and May Spare Steroids in Moderate-to-Severe Bullous Pemphigoid

Low‑Dose Interleukin‑2 Expands Regulatory T Cells and Modulates Biomarkers in Mild–Moderate Alzheimer’s Disease: Phase 2a Randomized Trial Shows Safety and Promising Signals

Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases